JP7525093B2 - 改変ｈ因子結合タンパク質 - Google Patents
改変ｈ因子結合タンパク質 Download PDFInfo
- Publication number
- JP7525093B2 JP7525093B2 JP2019511993A JP2019511993A JP7525093B2 JP 7525093 B2 JP7525093 B2 JP 7525093B2 JP 2019511993 A JP2019511993 A JP 2019511993A JP 2019511993 A JP2019511993 A JP 2019511993A JP 7525093 B2 JP7525093 B2 JP 7525093B2
- Authority
- JP
- Japan
- Prior art keywords
- fhbp
- pora
- modified
- loop
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101710186862 Factor H binding protein Proteins 0.000 title claims description 405
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 136
- 108090000623 proteins and genes Proteins 0.000 claims description 52
- 102000004169 proteins and genes Human genes 0.000 claims description 51
- 150000001413 amino acids Chemical class 0.000 claims description 46
- 239000000427 antigen Substances 0.000 claims description 43
- 102000036639 antigens Human genes 0.000 claims description 43
- 108091007433 antigens Proteins 0.000 claims description 43
- 238000003780 insertion Methods 0.000 claims description 40
- 230000037431 insertion Effects 0.000 claims description 40
- 239000000203 mixture Substances 0.000 claims description 23
- 102000016550 Complement Factor H Human genes 0.000 claims description 21
- 108010053085 Complement Factor H Proteins 0.000 claims description 21
- 238000006467 substitution reaction Methods 0.000 claims description 21
- 125000000539 amino acid group Chemical group 0.000 claims description 20
- 150000007523 nucleic acids Chemical class 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 230000027455 binding Effects 0.000 claims description 11
- 208000015181 infectious disease Diseases 0.000 claims description 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 238000012217 deletion Methods 0.000 claims description 8
- 230000037430 deletion Effects 0.000 claims description 8
- 108010060123 Conjugate Vaccines Proteins 0.000 claims description 6
- 238000007792 addition Methods 0.000 claims description 6
- 229940031670 conjugate vaccine Drugs 0.000 claims description 6
- 230000001717 pathogenic effect Effects 0.000 claims description 6
- 230000005847 immunogenicity Effects 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 230000006229 amino acid addition Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 229940031937 polysaccharide vaccine Drugs 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 3
- 239000013603 viral vector Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 description 52
- 235000018102 proteins Nutrition 0.000 description 44
- 229960005486 vaccine Drugs 0.000 description 26
- 239000012634 fragment Substances 0.000 description 21
- 230000002163 immunogen Effects 0.000 description 21
- 201000010099 disease Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 238000001262 western blot Methods 0.000 description 14
- 230000028993 immune response Effects 0.000 description 13
- 230000035772 mutation Effects 0.000 description 13
- 125000003277 amino group Chemical group 0.000 description 12
- 238000011160 research Methods 0.000 description 11
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 11
- 101710116435 Outer membrane protein Proteins 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 210000004899 c-terminal region Anatomy 0.000 description 9
- 238000000113 differential scanning calorimetry Methods 0.000 description 8
- 230000001681 protective effect Effects 0.000 description 8
- 239000002062 molecular scaffold Substances 0.000 description 7
- 108700028369 Alleles Proteins 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000003119 immunoblot Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 229940031348 multivalent vaccine Drugs 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000006641 stabilisation Effects 0.000 description 5
- 238000011105 stabilization Methods 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 208000037941 meningococcal disease Diseases 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 241000588650 Neisseria meningitidis Species 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 229940037003 alum Drugs 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 210000004201 immune sera Anatomy 0.000 description 3
- 229940042743 immune sera Drugs 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 206010018612 Gonorrhoea Diseases 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 208000034762 Meningococcal Infections Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 229940001442 combination vaccine Drugs 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 229940021993 prophylactic vaccine Drugs 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229940021747 therapeutic vaccine Drugs 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000737574 Homo sapiens Complement factor H Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027202 Meningitis bacterial Diseases 0.000 description 1
- 108700018753 Neisseria porin Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 108010013381 Porins Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000001948 anti-meningococcal effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 201000009904 bacterial meningitis Diseases 0.000 description 1
- 229960001212 bacterial vaccine Drugs 0.000 description 1
- 229940090821 bexsero Drugs 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940031416 bivalent vaccine Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 102000045512 human CFH Human genes 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 102000006392 myotrophin Human genes 0.000 description 1
- 108010058605 myotrophin Proteins 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 102000007739 porin activity proteins Human genes 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000000601 reactogenic effect Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1614687.0 | 2016-08-31 | ||
| GBGB1614687.0A GB201614687D0 (en) | 2016-08-31 | 2016-08-31 | fHbp scaffold |
| PCT/GB2017/052535 WO2018042178A1 (en) | 2016-08-31 | 2017-08-31 | Modified factor h binding protein |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019526261A JP2019526261A (ja) | 2019-09-19 |
| JP2019526261A5 JP2019526261A5 (enExample) | 2020-10-08 |
| JP7525093B2 true JP7525093B2 (ja) | 2024-07-30 |
Family
ID=57119942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019511993A Active JP7525093B2 (ja) | 2016-08-31 | 2017-08-31 | 改変ｈ因子結合タンパク質 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12497432B2 (enExample) |
| EP (1) | EP3506934A1 (enExample) |
| JP (1) | JP7525093B2 (enExample) |
| KR (1) | KR102643280B1 (enExample) |
| CN (1) | CN109890412B (enExample) |
| AU (1) | AU2017319218B2 (enExample) |
| BR (1) | BR112019003957A2 (enExample) |
| CA (1) | CA3035159A1 (enExample) |
| GB (2) | GB201614687D0 (enExample) |
| IL (1) | IL265078B2 (enExample) |
| MX (1) | MX420767B (enExample) |
| WO (1) | WO2018042178A1 (enExample) |
| ZA (1) | ZA201901862B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201614687D0 (en) * | 2016-08-31 | 2016-10-12 | Univ Oxford Innovation Ltd | fHbp scaffold |
| CN110903400A (zh) * | 2019-11-08 | 2020-03-24 | 苏州微超生物科技有限公司 | B群脑膜炎球菌fHBP多变体融合蛋白及其制备方法与应用 |
| CN111533792B (zh) | 2020-07-07 | 2020-10-16 | 康希诺生物股份公司 | 一种定点突变的载体蛋白及其在制备疫苗中的用途 |
| CN116323680A (zh) * | 2020-09-29 | 2023-06-23 | 出光兴产株式会社 | 肽标签和包含其的附加有标签的蛋白 |
| IN202321021121A (enExample) * | 2023-03-24 | 2024-04-19 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009517377A (ja) | 2005-11-25 | 2009-04-30 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | 髄膜炎菌のｎｍｂ１８７０のキメラ、ハイブリッドおよびタンデムポリペプチド |
| JP2013537884A (ja) | 2010-09-10 | 2013-10-07 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 髄膜炎菌に対するワクチン |
| WO2016083583A1 (en) | 2014-11-28 | 2016-06-02 | Crucell Holland B.V. | Meningitis b vaccine |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX339524B (es) * | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| US7351413B2 (en) * | 2002-02-21 | 2008-04-01 | Lorantis, Limited | Stabilized HBc chimer particles as immunogens for chronic hepatitis |
| US7785608B2 (en) * | 2002-08-30 | 2010-08-31 | Wyeth Holdings Corporation | Immunogenic compositions for the prevention and treatment of meningococcal disease |
| NZ562998A (en) * | 2002-10-11 | 2008-05-30 | Novartis Vaccines & Diagnostic | Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages |
| GB0227346D0 (en) * | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
| WO2004053091A2 (en) * | 2002-12-10 | 2004-06-24 | Lorantis Ltd. | STABILIZED IMMUNOGENIC HBc CHIMER PARTICLES |
| PT2172213E (pt) * | 2003-01-30 | 2013-06-03 | Novartis Ag | Vacinas injetáveis contra múltiplos serogrupos meningocócicos |
| NZ546430A (en) * | 2003-10-02 | 2009-04-30 | Novartis Vaccines & Diagnostic | Liquid vaccines for multiple meningococcal serogroups |
| GB0408977D0 (en) * | 2004-04-22 | 2004-05-26 | Chiron Srl | Immunising against meningococcal serogroup Y using proteins |
| GB2414667A (en) * | 2004-06-03 | 2005-12-07 | Isis Innovation | Vaccine compositions of N. meningitidis PorA and FetA antigens |
| WO2006011060A2 (en) * | 2004-07-23 | 2006-02-02 | Chiron Srl | Polypeptides for oligomeric assembly of antigens |
| GB0419408D0 (en) | 2004-09-01 | 2004-10-06 | Chiron Srl | 741 chimeric polypeptides |
| EP2682126B1 (en) * | 2005-01-27 | 2016-11-23 | Children's Hospital & Research Center at Oakland | GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis |
| EP1925318A1 (en) * | 2006-11-20 | 2008-05-28 | Paul-Ehrlich-Institut | Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu |
| WO2009104097A2 (en) * | 2008-02-21 | 2009-08-27 | Novartis Ag | Meningococcal fhbp polypeptides |
| ES2557282T3 (es) * | 2008-03-10 | 2016-01-25 | Children's Hospital & Research Center At Oakland | Proteínas quiméricas de unión al factor H (fHBP) que contienen un dominio B heterólogo, y métodos de uso |
| RU2477145C2 (ru) * | 2008-05-30 | 2013-03-10 | ДЗЕ Ю.Эс.Эй., ЭС РЕПРЕЗЕНТЕД БАЙ ДЗЕ СЕКРЕТАРИ ОФ ДЗЕ АРМИ, ОН БЕХАФ ОФ УОЛТЕР РИД АРМИ | Мультивалентная вакцина из нативных везикул наружной мембраны менингококков, способы ее получения и применения |
| WO2009150531A1 (en) * | 2008-06-09 | 2009-12-17 | Novartis Ag | Antibodies against neisserial factor h binding protein |
| WO2010028096A2 (en) * | 2008-09-03 | 2010-03-11 | Children's Hospital & Research Center At Oakland | Peptides presenting an epitope of an a domain of factor h binding protein and methods of use |
| GB0819633D0 (en) * | 2008-10-25 | 2008-12-03 | Isis Innovation | Composition |
| CN104548082A (zh) * | 2009-03-24 | 2015-04-29 | 诺华股份有限公司 | 为脑膜炎球菌因子h结合蛋白添加佐剂 |
| CA2759400A1 (en) * | 2009-04-30 | 2010-11-04 | Children's Hospital & Research Center At Oakland | Chimeric factor h binding proteins (fhbp) and methods of use |
| EP2470204B1 (en) * | 2009-08-27 | 2015-12-16 | GlaxoSmithKline Biologicals SA | Hybrid polypeptides including meningococcal fhbp sequences |
| CA2779816A1 (en) * | 2009-10-27 | 2011-05-05 | Novartis Ag | Modified meningococcal fhbp polypeptides |
| CN102869378A (zh) * | 2010-03-10 | 2013-01-09 | 葛兰素史密丝克莱恩生物有限公司 | 免疫原性组合物 |
| EP4036104B1 (en) * | 2010-03-30 | 2024-02-21 | Children's Hospital & Research Center at Oakland | Factor h binding proteins (fhbp) with altered properties and methods of use thereof |
| EP2556085A2 (en) * | 2010-04-05 | 2013-02-13 | Bar-Ilan University | Protease-activatable pore-forming polypeptides |
| EP2585106A1 (en) * | 2010-06-25 | 2013-05-01 | Novartis AG | Combinations of meningococcal factor h binding proteins |
| MY166172A (en) * | 2010-09-10 | 2018-06-07 | Wyeth Llc | Non-lipidated variants of neisseria meningitidis orf2086 antigens |
| WO2013078223A1 (en) * | 2011-11-23 | 2013-05-30 | Children's Hospital & Research Center Oakland | Anti-factor h binding protein antibodies and methods of use thereof |
| JP2015505309A (ja) * | 2011-12-29 | 2015-02-19 | ノバルティス アーゲー | 髄膜炎菌ｈ因子結合タンパク質のアジュバントされた組み合わせ |
| US10598666B2 (en) * | 2012-03-08 | 2020-03-24 | Glaxosmithkline Biologicals Sa | In vitro potency assay for protein-based meningococcal vaccines |
| CA2960030C (en) * | 2012-03-09 | 2020-02-25 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| SA115360586B1 (ar) * | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
| BR112014031386A2 (pt) * | 2012-06-14 | 2017-08-01 | Pasteur Institut | vacinas para meningococos do sorogrupo x |
| GB201215005D0 (en) * | 2012-08-23 | 2012-10-10 | Isis Innovation | Stabilised meningitis vaccine |
| EP2964665B1 (en) * | 2013-03-08 | 2018-08-01 | Pfizer Inc | Immunogenic fusion polypeptides |
| US20160030544A1 (en) * | 2013-03-14 | 2016-02-04 | Isis Innovation Limited | Immunogenic composition to neisseria |
| AU2014316722B2 (en) * | 2013-09-08 | 2017-09-07 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| EA034954B1 (ru) * | 2014-02-28 | 2020-04-10 | Глаксосмитклайн Байолоджикалс Са | МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp |
| EP3172224B1 (en) * | 2014-07-23 | 2022-06-29 | Children's Hospital & Research Center at Oakland | Factor h binding protein variants and methods of use thereof |
| KR20170103009A (ko) * | 2015-02-19 | 2017-09-12 | 화이자 인코포레이티드 | 나이세리아 메닌지티디스 조성물 및 그의 방법 |
| GB201614687D0 (en) * | 2016-08-31 | 2016-10-12 | Univ Oxford Innovation Ltd | fHbp scaffold |
| JP7010961B2 (ja) * | 2017-01-31 | 2022-02-10 | ファイザー・インク | 髄膜炎菌組成物およびその方法 |
-
2016
- 2016-08-31 GB GBGB1614687.0A patent/GB201614687D0/en not_active Ceased
-
2017
- 2017-08-31 JP JP2019511993A patent/JP7525093B2/ja active Active
- 2017-08-31 BR BR112019003957A patent/BR112019003957A2/pt unknown
- 2017-08-31 MX MX2019002248A patent/MX420767B/es unknown
- 2017-08-31 AU AU2017319218A patent/AU2017319218B2/en active Active
- 2017-08-31 GB GB1903866.0A patent/GB2568440B/en active Active
- 2017-08-31 US US16/328,340 patent/US12497432B2/en active Active
- 2017-08-31 KR KR1020197008694A patent/KR102643280B1/ko active Active
- 2017-08-31 EP EP17762178.6A patent/EP3506934A1/en active Pending
- 2017-08-31 CA CA3035159A patent/CA3035159A1/en active Pending
- 2017-08-31 WO PCT/GB2017/052535 patent/WO2018042178A1/en not_active Ceased
- 2017-08-31 CN CN201780060701.6A patent/CN109890412B/zh active Active
-
2019
- 2019-02-27 IL IL265078A patent/IL265078B2/en unknown
- 2019-03-26 ZA ZA2019/01862A patent/ZA201901862B/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009517377A (ja) | 2005-11-25 | 2009-04-30 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | 髄膜炎菌のｎｍｂ１８７０のキメラ、ハイブリッドおよびタンデムポリペプチド |
| JP2013537884A (ja) | 2010-09-10 | 2013-10-07 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 髄膜炎菌に対するワクチン |
| WO2016083583A1 (en) | 2014-11-28 | 2016-06-02 | Crucell Holland B.V. | Meningitis b vaccine |
Non-Patent Citations (1)
| Title |
|---|
| ＰＬＯＳ Ｐａｔｈｏｇｅｎｓ，Ｖｏｌ．８，Ｉｓｓｕｅ１０，ｅ１０００２９８１ |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019003957A2 (pt) | 2019-06-25 |
| CN109890412A (zh) | 2019-06-14 |
| US12497432B2 (en) | 2025-12-16 |
| ZA201901862B (en) | 2020-09-30 |
| GB201614687D0 (en) | 2016-10-12 |
| IL265078A (enExample) | 2019-04-30 |
| IL265078B1 (en) | 2023-04-01 |
| EP3506934A1 (en) | 2019-07-10 |
| AU2017319218A2 (en) | 2019-05-02 |
| NZ751995A (en) | 2024-03-22 |
| KR20190064577A (ko) | 2019-06-10 |
| CA3035159A1 (en) | 2018-03-08 |
| IL265078B2 (en) | 2023-08-01 |
| CN109890412B (zh) | 2025-04-04 |
| GB2568440B (en) | 2022-08-17 |
| GB2568440A (en) | 2019-05-15 |
| AU2017319218B2 (en) | 2021-10-28 |
| KR102643280B1 (ko) | 2024-03-05 |
| WO2018042178A1 (en) | 2018-03-08 |
| JP2019526261A (ja) | 2019-09-19 |
| US20220112249A1 (en) | 2022-04-14 |
| MX2019002248A (es) | 2019-09-18 |
| AU2017319218A1 (en) | 2019-04-18 |
| GB201903866D0 (en) | 2019-05-08 |
| MX420767B (es) | 2025-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7525093B2 (ja) | 改変ｈ因子結合タンパク質 | |
| JP5676458B2 (ja) | 変異ｈ因子結合タンパク質を含むワクチン組成物 | |
| JP7271654B2 (ja) | 改変された髄膜炎菌ｆＨｂｐポリペプチド | |
| Aston-Deaville et al. | An assessment of the use of Hepatitis B Virus core protein virus-like particles to display heterologous antigens from Neisseria meningitidis | |
| US10279026B2 (en) | Antigens and antigen combinations | |
| US20190290748A1 (en) | Antigens and antigen combinations | |
| ES2912751T3 (es) | Composiciones inmunogénicas y vacunas derivadas de proteínas receptoras de superficie bacteriana | |
| RU2773464C1 (ru) | Модифицированный белок, связывающий фактор н | |
| KR20080108576A (ko) | Ｎｍｂ0606 단백질을 포함하는 약학적 조성물 | |
| CN101448522A (zh) | 包含蛋白质nmb0938的药物组合物 | |
| McCarvil et al. | Expression of meningococcal epitopes in LamB of Escherichia coli and the stimulation of serosubtype‐specific antibody responses | |
| WO2005054282A1 (es) | Proteína nmb0928 y su uso en formulaciones farmaceuticas | |
| OA19655A (en) | Modified factor H binding protein. | |
| ES2334138T3 (es) | Proteina nmb1125 y uso de la misma en formulaciones farmaceuticas. | |
| EA046480B1 (ru) | МОДИФИЦИРОВАННЫЕ ПОЛИПЕПТИДЫ МЕНИНГОКОККОВОГО fHbp | |
| KR20080081198A (ko) | 단백질 ｎｍａ0939를 포함하는 약학적 조성물 | |
| WO2009056075A1 (es) | Composición farmacéutica que comprende la proteína nmb0873 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190517 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200828 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200828 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210623 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210629 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210924 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211125 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220329 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220729 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20220729 |
|
| C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20220809 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20220906 |
|
| C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20220913 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20221118 |
|
| C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20221122 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240319 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240705 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7525093 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |